News|Podcasts|December 16, 2024

Diabetes Dialogue: Celebrating 2024 - The Year of the Continuous Glucose Monitor

Name: Diabetes Dialogue: Celebrating 2024 - The Year of the Continuous Glucose Monitor
Uploaded: 2024-12-16T11:00:00Z
Duration: 18 min 23 s
Description: Diabetes Dialogue: Celebrating 2024 - The Year of the Continuous Glucose Monitor

Author(s)Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCES

In this episode, hosts reflect on the advancement in CGM that reshaped care for diabetes and overall health during 2024.

Welcome to this special edition of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, hosted by Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center.

Related to this article

David Kendall, MD | Image Credit: LinkedIn

October 7th, 2026

ZUPREME-2: Petrelintide Outperforms Placebo for Weight Loss in T2D and Obesity

Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.

October 4th, 2026

8 Endocrinology Headlines You Missed in Q3 2026

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

October 9th, 2026

Liver Lineup: What's New in the ACG Hepatic Encephalopathy Guideline

Jasmohan Bajaj, MD, joins Nancy Reau, MD, and Kim Brown, MD, to review what is new in the ACG hepatic encephalopathy guideline.

W. Timothy Garvey, MD | Image Credit: UAB

October 7th, 2026

New Injectable Substantially Reduces Visceral Adipose Tissue in Obesity

Presented at EASD 2026, the present analysis discusses CBL-514’s apparent efficacy in reducing L2-L3 visceral fat compared to placebo.

Atopic Dermatitis Pipeline and Remibrutinib for Dermographism

October 11th, 2026

Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism

Raj Chovatiya, MD, PhD, discusses biologic choice in atopic dermatitis, pipeline strategies, and remibrutinib’s approval for symptomatic dermographism.

Christopher Maulion, MD | Image Credit: Yale School of Medicine

October 11th, 2026

GLP-1 Initiation in Heart Failure Reduces Pulmonary Artery Pressure, Hospitalizations

A recent retrospective analysis presented at HFSA 2026 has demonstrated the association between GLP-1 agonists, weight reduction, and PA pressures.

Theodore Abraham, MD | Image Credit: UCSF Health

October 11th, 2026

Aficamten Improves Right Ventricular Strain, Systolic Pressure in oHCM

A new analysis of the SEQUOIA-HCM trial, presented at HFSA 2026, demonstrates aficamten’s association with improvements to an understudied aspect of the condition.

Hareem Saleem, MBBS | Image Credit: LinkedIn

October 10th, 2026

Finerenone Outperforms Spironolactone, Eplerenone in HFpEF, HFmrEF Renal Outcomes

A recent network meta-analysis presented at HFSA 2026 displays finerenone’s favorable safety profile and comparatively greater reduction of acute kidney injury risk.